Idera Pharmaceuticals Reports Promising Data from Ongoing Phase 1 Dose Escalation in Clinical Trial of Intra-tumoral IMO-2125 in Combination with Ipilimumab in Patients with PD-1 Refractory Metastatic Melanoma

– 3 Patients with PD-1 Refractory Cutaneous Melanoma are Responders Including One Complete Response (CR) –

– Driven by Increased Prioritization of IMO-2125 Clinical Development, Company Suspends Development of IMO-8400 for B-Cell Lymphomas –

CAMBRIDGE,

Related Post
Patton offers a unique set of competencies and capabilities that help companies bring their UC
WATERTOWN, Mass., Oct. 13, 2017 (GLOBE NEWSWIRE) — Mimecast Limited (NASDAQ:MIME), a leading email and
GAITHERSBURG, Md., Oct. 13, 2017 (GLOBE NEWSWIRE) — Patton Electronics—US manufacturer of UC, cloud, and